SIROLIMUS vs TACROLIMUS OINTMENT 0.1%

Compare SIROLIMUS (sirolimus) and TACROLIMUS OINTMENT 0.1% (Tacrolimus) — clinical data, side effects, and patient experiences.

SIROLIMUS

sirolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Sirolimus inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin [IL]-2, IL-4, and IL-15) stimul...

Approved for

1.2

it is recommended that sirolimus tablets be used initially in a regimen with cyclosporine and corticosteroids

peak PRA level > 80%])

it is recommended that sirolimus tablets be used in combination with cyclosporine and corticosteroids for the first year following transplantation [ see Dosage and Administration ( 2.3 )

OralTablet

TACROLIMUS OINTMENT 0.1%

Tacrolimus · Immunosuppressant

How it works

Other agent

Approved for

INDICATIONS AND USAGE Tacrolimus ointment

both 0.03% and 0.1% for adults

and only 0.03% for children aged 2 to 15 years

or when those treatments are not advisable. Tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed WARNING

TopicalTablet

Quick Comparison

SIROLIMUSTACROLIMUS OINTMENT 0.1%

Drug Class

Immunosuppressant

Route

Oral

Topical

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SIROLIMUS

Drug Not Working

>10%

Fever

1-10%

Diarrhea

1-10%

Condition Worsened

0.1-1%

TACROLIMUS OINTMENT 0.1%

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

FDA Warnings

SIROLIMUS

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions ( 5
12 ) Increased Risk of Calcineurin Inhibitor-Induced Hemolytic Uremic Syndrome/ Thrombotic Thrombocytopenic Purpura/ Thrombotic Microangiopathy ( 5
Oversuppression of the immune system can also increase susceptibility to infection, including opportunistic infections such as tuberculosis, fatal infections, and sepsis
Many of these patients had evidence of infection at or near the time of death

TACROLIMUS OINTMENT 0.1%

WARNING Long-term Safety of Topical Calcineurin Inhibitors Has Not Been Established Although a causal relationship has not been established, rare cases of malignancy (e

Clinical Trial Data

No head-to-head clinical studies found for SIROLIMUS vs TACROLIMUS OINTMENT 0.1%.

SIROLIMUS vs TACROLIMUS OINTMENT 0.1%: What You Should Know

Key Differences

Both SIROLIMUS and TACROLIMUS OINTMENT 0.1% belong to the Immunosuppressant class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. SIROLIMUS is administered via Oral, whereas TACROLIMUS OINTMENT 0.1% uses Topical. Route of administration can affect onset of action and patient adherence.

Safety Considerations

SIROLIMUS carries 4 FDA warnings. TACROLIMUS OINTMENT 0.1% carries 1 FDA warning. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

EVEROLIMUS vs SIROLIMUS→CYCLOSPORINE OPHTHALMIC SOLUTION vs SIROLIMUS→CYCLOSPORINE vs SIROLIMUS→MYCOPHENILIC ACID vs SIROLIMUS→AZATHIOPRINE vs SIROLIMUS→SIROLIMUS vs TACROLIMUS EXTENDED-RELEASE CAPSULES→

Loading comparison data...

SIROLIMUS vs TACROLIMUS OINTMENT 0.1%

Compare SIROLIMUS (sirolimus) and TACROLIMUS OINTMENT 0.1% (Tacrolimus) — clinical data, side effects, and patient experiences.

SIROLIMUS

sirolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Sirolimus inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin [IL]-2, IL-4, and IL-15) stimul...

Approved for

1.2

it is recommended that sirolimus tablets be used initially in a regimen with cyclosporine and corticosteroids

peak PRA level > 80%])

it is recommended that sirolimus tablets be used in combination with cyclosporine and corticosteroids for the first year following transplantation [ see Dosage and Administration ( 2.3 )

OralTablet

TACROLIMUS OINTMENT 0.1%

Tacrolimus · Immunosuppressant

How it works

Other agent

Approved for

INDICATIONS AND USAGE Tacrolimus ointment

both 0.03% and 0.1% for adults

and only 0.03% for children aged 2 to 15 years

or when those treatments are not advisable. Tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed WARNING

TopicalTablet

Quick Comparison

SIROLIMUSTACROLIMUS OINTMENT 0.1%

Drug Class

Immunosuppressant

Route

Oral

Topical

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SIROLIMUS

Drug Not Working

>10%

Fever

1-10%

Diarrhea

1-10%

Condition Worsened

0.1-1%

TACROLIMUS OINTMENT 0.1%

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

FDA Warnings

SIROLIMUS

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions ( 5
12 ) Increased Risk of Calcineurin Inhibitor-Induced Hemolytic Uremic Syndrome/ Thrombotic Thrombocytopenic Purpura/ Thrombotic Microangiopathy ( 5
Oversuppression of the immune system can also increase susceptibility to infection, including opportunistic infections such as tuberculosis, fatal infections, and sepsis
Many of these patients had evidence of infection at or near the time of death

TACROLIMUS OINTMENT 0.1%

WARNING Long-term Safety of Topical Calcineurin Inhibitors Has Not Been Established Although a causal relationship has not been established, rare cases of malignancy (e

Clinical Trial Data

No head-to-head clinical studies found for SIROLIMUS vs TACROLIMUS OINTMENT 0.1%.

SIROLIMUS vs TACROLIMUS OINTMENT 0.1%: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.